These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 2908814)

  • 21. Effects of fenoldopam on renal blood flow and systemic hemodynamics during isoflurane anesthesia.
    Aronson S; Goldberg LI; Glock D; Roth S; Moss J; Roizen MF
    J Cardiothorac Vasc Anesth; 1991 Feb; 5(1):29-32. PubMed ID: 1678284
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects.
    Contreras F; Foullioux C; Pacheco B; Maroun C; Bolívar H; Lares M; Leal E; Cano R; Bermúdez V; Velasco M
    Am J Ther; 2008; 15(4):397-402. PubMed ID: 18645345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of catechol ring fluorination on cardiovascular and renal activities of fenoldopam enantiomers.
    Kinter LB; Mann WA; Weinstock J; Ruffolo RR
    Chirality; 1994; 6(5):446-55. PubMed ID: 7915128
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years.
    Kisicki JC; Fiske K; Lyne A
    Clin Ther; 2007 Sep; 29(9):1967-79. PubMed ID: 18035196
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained hemodynamic effects of the selective dopamine-1 agonist, fenoldopam, during 48-hour infusions in hypertensive patients: a dose-tolerability study.
    Taylor AA; Mangoo-Karim R; Ballard KD; Luther RR; Pool JL
    J Clin Pharmacol; 1999 May; 39(5):471-9. PubMed ID: 10234594
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Selective dopamine-1 receptor agonist augments regional myocardial blood flow: comparison of fenoldopam and dopamine.
    Shi Y; Zalewski A; Bravette B; Maroko AR; Maroko PR
    Am Heart J; 1992 Aug; 124(2):418-23. PubMed ID: 1353297
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and pharmacologic activity of a new nitrate ester, ITF 296, after intravenous administration in healthy volunteers.
    Sardina M; Love R; Mizrahi J; Monzani V; Bianchini C
    J Cardiovasc Pharmacol; 1995; 26 Suppl 4():S72-9. PubMed ID: 8839230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lithium and the renal response to gludopa, fenoldopam and dopamine.
    Girbes AR; Smit AJ; Meijer S; Reitsma WD
    Br J Clin Pharmacol; 1990 Oct; 30(4):652-3. PubMed ID: 1981323
    [No Abstract]   [Full Text] [Related]  

  • 29. Lithium and the natriuretic response to gludopa, fenoldopam and dopamine.
    Schoors DF; Dupont AG
    Br J Clin Pharmacol; 1990 Oct; 30(4):651-2. PubMed ID: 1981322
    [No Abstract]   [Full Text] [Related]  

  • 30. Selective peripheral dopamine-1 receptor stimulation with fenoldopam in human essential hypertension.
    Carey RM; Stote RM; Dubb JW; Townsend LH; Rose CE; Kaiser DL
    J Clin Invest; 1984 Dec; 74(6):2198-207. PubMed ID: 6150942
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fenoldopam, but not nitroprusside, improves renal function in severely hypertensive patients with impaired renal function.
    Shusterman NH; Elliott WJ; White WB
    Am J Med; 1993 Aug; 95(2):161-8. PubMed ID: 8102835
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cardiovascular and renal profile of acute peripheral dopamine1-receptor agonism with fenoldopam.
    Glück Z; Jossen L; Weidmann P; Gnädinger MP; Peheim E
    Hypertension; 1987 Jul; 10(1):43-54. PubMed ID: 2885268
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ontogeny of renal response to specific dopamine DA1-receptor stimulation in sheep.
    Segar JL; Smith FG; Guillery EN; Jose PA; Robillard JE
    Am J Physiol; 1992 Oct; 263(4 Pt 2):R868-73. PubMed ID: 1357989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of food on pharmacokinetics and pharmacodynamics of fenoldopam in class III heart failure.
    Blanchett DG; Green JA; Nara A; Pospisil R; Jarvis RC; Kasmer RJ; Boyle DA; Cyronak MJ; Corder CN
    Clin Pharmacol Ther; 1991 Apr; 49(4):449-56. PubMed ID: 1673097
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative effects of fenoldopam mesylate and nitroprusside on left ventricular performance in severe systemic hypertension.
    Hackman BB; Griffin B; Mills M; Ramanathan KB
    Am J Cardiol; 1992 Apr; 69(9):918-22. PubMed ID: 1347965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of intravenous fenoldopam mesylate in the management of severe systemic hypertension.
    Munger MA; Rutherford WF; Anderson L; Hakki AI; Gonzalez FM; Bednarczyk EM; Emmanuel G; Weed SG; Panacek EA; Green JA
    Crit Care Med; 1990 May; 18(5):502-4. PubMed ID: 1970283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of dopamine and a dopamine D-1 receptor agonist on pulsatile thyrotrophin secretion in normal women.
    Boesgaard S; Hagen C; Hangaard J; Andersen AN; Eldrup E
    Clin Endocrinol (Oxf); 1990 Apr; 32(4):423-31. PubMed ID: 1971778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of fenoldopam on intracranial pressure and hemodynamic variables at normal and elevated intracranial pressure in anesthetized pigs.
    Hennes HJ; Jantzen JP
    J Neurosurg Anesthesiol; 1994 Jul; 6(3):175-81. PubMed ID: 7915922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical experience with intravenous fenoldopam.
    Holcslaw TL; Beck TR
    Am J Hypertens; 1990 Jun; 3(6 Pt 2):120S-125S. PubMed ID: 1974440
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of lithium on the renal response to DA1-dopamine receptor stimulation by fenoldopam in normal man.
    Girbes AR; Smit AJ; Meijer S; Reitsma WD
    Br J Clin Pharmacol; 1990 Apr; 29(4):413-5. PubMed ID: 1970264
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.